# ScoreItem: Urobilinogênio

**ID:** `019bf31d-2ef0-76fd-b607-70a089918780`
**FullName:** Urobilinogênio (Exames - Laboratoriais)
**Unit:** mg/dL

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 5 artigos
- Avg Similarity: 0.635

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-76fd-b607-70a089918780`.**

```json
{
  "score_item_id": "019bf31d-2ef0-76fd-b607-70a089918780",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Urobilinogênio (Exames - Laboratoriais)
**Unidade:** mg/dL

**30 chunks de 5 artigos (avg similarity: 0.635)**

### Chunk 1/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** methods | **Similarity:** 0.699

ReviewArmandoRaúlGuerraRuiz*,JavierCrespo,RosaMariaLópezMartínez,PaulaIruzubieta,GregoriCasalsMercadal,MartaLalanaGarcés,BernardoLavinandManuelMoralesRuizMeasurementandclinicalusefulnessofbilirubininliverdiseasehttps://doi.org/10.1515/almed-2021-0047ReceivedDecember2,2020;acceptedFebruary16,2021;
publishedonlineJuly9,2021Abstract:Elevatedplasmabilirubinlevelsareafrequentclinicalfinding.Itcanbesecondarytoalterationsinanystageofitsmetabolism:(a)excessbilirubinproduction(i.e.,pathologichemolysis);(b)impairedliveruptake,withelevationofindirectbilirubin;(c)impairedconjugation,promptedbyadefectintheUDP-glucuronosyltransferase;and(d)bileclearancedefect,withelevationofdirectbili-rubinsecondarytodefectsinclearanceproteins,orinabilityofthebiletoreachthesmallbowelthroughbileducts.Aliverlesionofanycausereduceshepatocytecellnumberandmayimpairtheuptakeofindirectbilirubinfromplasmaanddiminishdirectbilirubintransportandclearance
throughthebileducts.Variousanalyticalmethodsare
currentlyavailablefor

---

### Chunk 2/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** methods | **Similarity:** 0.696

ismandrecirculation.354
GuerraRuizetal.:Bilirubin:measurementandclinicalusefulness

lowergastrointestinaltract,thethreeurobilinogensspon-taneouslyoxidizetoproducetheequivalentbrownish-yellowbilepigmentsstercobilinogen,urobilinogen,andmesobilinogen,givingstoolitsdistinctivecolor.Upto20%oftheurobilinogenproduceddailyisreabsorbedfromtheintestineandundergoesenterohepaticrecirculation.Mostofthisurobilinogenistakenupbytheliver(viatheportalvein)andisreexcretedintobile,whereasasmallfraction(2–5%)isexcretedintothegeneralcirculationandlteredbythekidneys,beingdetectableinurine.TestingmethodsVariousanalyticalmethodsarecurrentlyavailableformeasuringbilirubinanditsmetabolitesinserum,urine,andfeces.Serumbilirubinisdeterminedby:(i)diazotransferreaction,currently,thegold-standardmeasurementmethod;(ii)high-performanceliquidchromatography(HPLC);(iii)oxidative,enzymatic,andchemicalmethods;(iv)directspectrophotometry;and(v)transcutaneousmethods[15].Sinceitwasfirstdescribedbytheendofthe19thcentury,themos

---

### Chunk 3/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** results | **Similarity:** 0.689

_12Bacteroides cellulosilyticus CL02T12C19Bacteroides finegoldii CL09T03C10E. coli BL21E. coli 5­alphaClostridium citroniae WAL­17109Clostridium innocuum 6_1_30L. reuteri CF48­3ARuminococcus gnavus CC55_001CClostridium bolteae CC43_001BClostridioides diicile P11Clostridioides diicile Isolate 7Clostridioides diicile CD3Clostridioides diicile P720406080Sample­to­blank ratioStercobilinUrobilinConjugatedbilirubinBilirubinUrobilinogenHMOX1BLVRABiliverdinUGT1A1
Fig. 1 | Identification of bilirubin-reducing bacterial strains. a, Illustrated representation of the haem degradation pathway. Key human enzymes are labelled with grey text. b, Diagram of the structures of bilirubin and urobilinogen. The bonds reduced during bilirubin reduction are shown in red. c, Results of fluorescence assay screening of bacterial strains. Measurements from n=3 independent biological replicates are shown as black points.

---

### Chunk 4/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** results | **Similarity:** 0.675

hbilirubinandurobilinogendeterminationinserumandurine.Inthehospitalcontext,bilirubinconcen-trationsareveryusefulforprognosisofacuteliverdiseaseandmonitoringchronicliverdisease.Theseresultsmustbeinterpretedinthecontextofpatientanamnesis,degreeofalteration,andotherclinicallaboratoryparameters.Acknowledgments:TheauthorsthanktheSpanishSocietyofLaboratoryMedicine(SEQC-ML)andtheSpanishSocietyofDigestiveDiseases(SEPD)andtheirscientificboardsfortheirsupport.Researchfunding:1)MinisteriodeEconomíayCom-petitividad(PID2019-105502RB-I00aMM-R).2)ProyectoPI19/00774,nanciadoporelInstitutodeSaludCarlosIIIyconanciadoporlaUniónEuropea(FEDER).3)ProyectoPI15/02138,nanciadoporelInstitutodeSaludCarlosIII.4)ProyectoFISPI18/01304,nanciadoporelInstitutodeSaludCarlosIII.

---

### Chunk 5/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.669

ia)whereasurinehasexcesscolor(choluria)andurineurobilinogenisdecreased[1].Extra-hepaticcholestasiscanbecausedbyatotalorpartialphysicalobstructionofextrahepaticbileducts.Themostcommoncausesinclude:choledocholithiasis,extrinsiccompressionsofthebileduct(pancreaticneoplasia,Mir-
izzisyndrome),disordersoftheextrahepaticbileducts(cholangiocarcinoma,primaryorsecondarysclerosingcholangitis),andinfections(CMV,parasites).BilirubinasadiagnosticandprognosticmarkerInliverdiseaseAsmentionedabove,elevationofbilirubinconcentrationscanbeinducedbynumerouscausesandhence,itisanonspecificmarkerofliverdysfunction.Itisnotasensitivemarkerofliverinjuryeither:ahealthylivercanconjugatedailyUCBproductionuptotwotimeswithoutcausinganincreaseintotalbilirubinconcentrations.Also,therateof
bilirubinexcretionis10timeshigherthantherateofbili-rubinproduction[39].However,hyperbilirubinemiaisalong-establishedmarkerofliverandbilealterations,andhasprognosticvalueincertainliverdiseases[3,40].Inthehyperacutestageofacuteliverfai

---

### Chunk 6/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** introduction | **Similarity:** 0.654

ubin;cholestasis;diazomethod;liverdisease.IntroductionBilirubinisanorange-yellowpigmentofbilethatresultsfromthedegradationofvariousheme-containingproteins,
especiallyfromhemoglobincatabolism.Hemeisbroken
downintobiliverdin,whichisconvertedintounconju-
gatedorindirectbilirubin(UCB).UCBiswater-insoluble
andenterscirculationboundtoalbumin.Intheliver,
glucuronicacidisaddedtoUCB(conjugation)torenderit
water-soluble(directbilirubin);finally,itiseitherexcreted
intobileorrecirculatedbacktothebloodstream,whereitis
filtratedbythekidneysandexcretedthroughurine[1].Elevationofplasmabilirubinlevelsisafrequentfindingbothinprimary[2]andhospitalcare.Allliverle-
sionsinduceadecreaseinthehepatocytecellcount,which
maycausehyperbilirubinemia[3].Hyperbilirubinemiacan
originatefromanalterationinanystageofbilirubinmetabolism:excessproduction,impairedliveruptake,conjugationdefects,orbiliaryexcretiondefects[4].Bilirubinisawell-establishedmarkerthatisroutinelyincludedinbiochemicaltestsforpatientswithliver
dysfun

---

### Chunk 7/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.652

henexposedtolightandstoredatroomtemperatureandcanoxidizetobiliverdin(negativediazo)atthenormallyacidpHofurine.Iftestingisdelayed,thesamplemustbekeptinadarkplaceandstoredat2–8°Cforamaximumof24h.Thismethodmaybeaffectedbypositive(ascorbicacid,nitrites)andnegative(substancesthatgiveurineabrownish/redcolorsuchasdrugsormetabolites,i.e.,rifampicin)interferences[29].Itisworthmentioningthatconcurrenturobilinogendeterminationwiththesamereactivestripprovidesguid-anceaboutthenatureofthebilirubinmetabolismdisorder.Elevatedurobilinogenlevelswithconcomitantincreasedornormalbilirubinaresuggestiveofincreasedhemolysisorliverdisease,withelevatedenterohepaticcirculation.Incontrast,elevatedbilirubinconcentrationswithnormalurobilinogenlevelsindicatereducedCBsecretionintotheintestine,asincasesofbileductobstruction.RequirementsforbilirubintestingTherequirementsfortestingbilirubinvaryslightlydepend-
ingonitsuse.AccordingtoCLIAguidelines,atotalerrorof20%orlessisrequired.Also,thequalitystandardsestab-lishedby

---

### Chunk 8/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** methods | **Similarity:** 0.650

humeauxD.Inheriteddisordersofbilirubintransportandconjugation:newinsightsintomolecular
mechanismsandconsequences.Gastroenterology2014;146:1625–38.12.RowlandA,MinersJO,MackenziePI.TheUDP-glucuronosyltransferases:theirroleindrugmetabolismanddetoxication.IntJBiochemCellBiol2013;45:1121–32.13.JemnitzK,Heredi-SzaboK,JanossyJ,IojaE,VereczkeyL,KrajcsiP.ABCC2/Abcc2:amultispecictransporterwithdominantexcretoryfunctions.DrugMetabRev2010;42:402–36.14.PellockSJ,RedinboMR.Glucuronidesinthegut:sugar-drivensymbiosesbetweenmicrobeandhost.JBiolChem2017;292:
8569–76.15.NgashangvaL,BachuV,GoswamiP.Developmentofnewmethodsfordeterminationofbilirubin.JPharmaceutBiomed
Anal2019;162:272–85.16.KwoPY,CohenSM,LimJK.ACGclinicalguideline:evaluationofabnormalliverchemistries.AmJGastroenterol2017;112:18–35.17.ColePG,LatheGH,BillingBH.Thediazoreactingpigmentsofserum,urineandbile.BiochemJ1953;55:xiii.18.KuenzleCC,MaierC,RüttnerJR.Thenatureoffourbilirubinfractionsfromserumandofthreebilirubinfractionsfrom

---

### Chunk 9/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** results | **Similarity:** 0.644

e-hepatic,hepatic,orpost-hepatic.Pre-hepatichyperbilirubinemiaThetermreferstohyperbilirubinemiasecondarytoexcessbilirubinproduction.Themostcommoncauseisacceler-atedhemolysis.Whenanelevatedbilirubinproduction
rateexceedstheuptakeandexcretioncapacityoftheliver,itresultsinelevatedserumUCBconcentrations,whereasCBcanbenormalorslightlyelevated.Identifyinghemo-lysisasthecauseofhyperbilirubinemiaisnotchallenging,sincethepatientwillexhibitothernumerouscueingsigns(anemia,elevatedreticulocytes,amongothers)[1].Sinceelevatedbilirubinisnotinducedbyliverdamage,testingwillnotshowalterationsinaminotransferases,albumin,orprothrombinactivity.HepatichyperbilirubinemiasThetermreferstoconditionsdirectlyrelatedtoliver
function.Theseconditionsmayaffectbilirubinuptake,metabolism,conjugation,and/orexcretion,andtestswillshowelevatedCBand/orUCBconcentrations.Thesediseasesareassociatedwithconcomitantliverlesionsofdifferentseveritythatmaycompromiseliverfunctionandmightfollowanacuteorchroniccourse.Espe-ciallyintheca

---

### Chunk 10/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** abstract | **Similarity:** 0.643

Elevatedplasmabilirubinlevelsareafrequentclinicalfinding.Itcanbesecondarytoalterationsinanystageofitsmetabolism:(a)excessbilirubinproduction(i.e.,pathologichemolysis);(b)impairedliveruptake,withelevationofindirectbilirubin;(c)impairedconjugation,promptedbyadefectintheUDP-glucuronosyltransferase;and(d)bileclearancedefect,withelevationofdirectbili-rubinsecondarytodefectsinclearanceproteins,orinabilityofthebiletoreachthesmallbowelthroughbileducts.Aliverlesionofanycausereduceshepatocytecellnumberandmayimpairtheuptakeofindirectbilirubinfromplasmaanddiminishdirectbilirubintransportandclearance
throughthebileducts.Variousanalyticalmethodsare
currentlyavailableformeasuringbilirubinanditsmetabo-
litesinserum,urineandfeces.Serumbilirubinisdeter-
minedby(1)diazotransferreaction,currently,thegold-
standard;(2)high-performanceliquidchromatography
(HPLC);(3)oxidative,enzymatic,andchemicalmethods;(4)
directspectrophotometry;and(5)transcutaneousmethods.
Althoughbilirubinisawell-establishedmarkerofliver
function,itdoesnotalwaysidentifyalesioninthisorgan.Therefore,foraccuratediagnosis,alterationsinbilirubinconcentrationsshouldbeassessedinrelationtopatient
anamnesis,thedegreeofthealteration,andthepatternof
concurrentbiochemicalalterations.

---

### Chunk 11/30
**Article:** Bilirubin metabolism and jaundice: advances in understanding and clinical implications (2021)
**Journal:** Seminars in Liver Disease
**Section:** abstract | **Similarity:** 0.632

Bilirubin, the end product of heme catabolism, has long been considered merely a waste product.
Recent evidence demonstrates that mildly elevated unconjugated bilirubin levels exert beneficial antioxidant and
anti-inflammatory effects. This review discusses the complete bilirubin metabolism pathway, from heme degradation
through hepatic conjugation and biliary excretion. Understanding the differences between unconjugated (indirect)
and conjugated (direct) hyperbilirubinemia is essential for proper differential diagnosis. Hemolytic disorders,
Gilbert syndrome, and Crigler-Najjar syndrome cause predominantly unconjugated hyperbilirubinemia, while hepatocellular
disease and cholestasis result in conjugated hyperbilirubinemia. The clinical approach includes fractionation of
total bilirubin and assessment of associated liver function tests.

---

### Chunk 12/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.632

bilirubinemia and breast milk-induced jaundice. Drug 
Metab. Dispos. 46, 17451755 (2018).31. Koníčková, R. et al. Reduction of bilirubin ditaurate by the 
intestinal bacterium Clostridium perfringens. Acta Biochim. Pol. 59, 289292 (2012).32. Vítek, L. & Ostrow, J. D. Bilirubin chemistry and metabolism; 
harmful and protective aspects. Curr. Pharm. Des. 15, 28692883 (2009).33. Zhou, S. et al. Association of serum bilirubin in newborns aected 
by jaundice with gut microbiota dysbiosis. J. Nutr. Biochem. 63, 5461 (2019).34. Vítek, L., Novotný, L., Sperl, M., Holaj, R. & Spácil, J. The inverse 
association of elevated serum bilirubin levels with subclinical 
carotid atherosclerosis. Cerebrovasc. Dis. 21, 408414 (2006).35. The Integrative HMP (iHMP) Research Network Consortium. The 
integrative human microbiome project. Nature 569, 641648 (2019).36. Naumann, H. N. Schlesingers test for urobilin in the presence of 
ribolavin and other luorescent compounds. J. Lab.

---

### Chunk 13/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.632

iti-cal role in human physiology through the gutliver axis1. Alongside other organic molecules in bile such as cholesterol and bile acids, bilirubin diglucuronide (conjugated bilirubin) is secreted into the gut where it is either excreted or reabsorbed. When bilirubin diglucuronide is decon-jugated by human or bacterial beta-glucuronidases into unconjugated bilirubin, it can be readily reabsorbed into the enterohepatic circulation or further metabolized via reduction reactions by gut microorganisms into the more excretable metabolites urobilinogen and stercobilinogen2. Bilirubin reabsorption elevates serum bilirubin levels, while excretion as urobilinogen and stercobilinogen in stool and urine facilitates its clearance, completing the haem degradation pathway35 (Fig. 1a).Dysregulation of gut microbial bilirubin reduction affects serum bilirubin levels, which can have substantial health implications.

---

### Chunk 14/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.627

17;87:e1–294.e8.37.WolkoffAW,KetleyJN,WaggonerJG,BerkPD,JakobyWB.Hepaticaccumulationandintracellularbindingofconjugatedbilirubin.JClinInvest1978;61:142–9.38.Méndez-SánchezN,VítekL,Aguilar-OlivosNE,UribeM.Bilirubinasabiomarkerinliverdisease.In:Biomarkersinliverdisease.Dordrecht:Springer;2017:281–304pp.39.RaymondGD,GalambosJT.Hepaticstorageandexcretionofbilirubininman.AmJGastroenterol1971;55:135–44.40.SticovaE,JirsaM.Newinsightsinbilirubinmetabolismandtheirclinicalimplications.WorldJGastroenterol2013;19:
6398–407.41.RutherfordA,KingLY,HynanLS,VedvyasC,LinW,LeeWM,etal.Developmentofanaccurateindexforpredictingoutcomesof
patientswithacuteliverfailure.Gastroenterology2012;143:
1237–43.42.WlodzimirowKA,EslamiS,Abu-HannaA,NieuwoudtM,ChamuleauRAFM.Asystematicreviewonprognosticindicators360
GuerraRuizetal.:Bilirubin:measurementandclinicalusefulness

ofacuteonchronicliverfailureandtheirpredictivevalueformortality.LiverInt2013;33:40–52.43.HelmkeS,ColmeneroJ,EversonGT.Noninvasiveas

---

### Chunk 15/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** results | **Similarity:** 0.627

with and 
without hyperbilirubinemia. Dig Dis Sci 2008;53:799-
802.163. Lazo M, Selvin E, Clark JM. Brief communication: 
clinical implications of short-term variability in liver 
function test results. Ann Intern Med 2008;148:348-52.164. Schmidt E, Schmidt FW, Chemnitz G, Kubale R, 
Lobers J. The Szasz-ratio (CK/GOT) as example for the 
diagnostic significance of enzyme ratios in serum. Klin 
Wochenschr 1980;58:709-18.165. Dufour DR. Is it necessary to order aspartate 
aminotransferase with alanine aminotransferase 
in clinical practice? Author’s Reply. Clin Chem 
2001;47:1134-5.

---

### Chunk 16/30
**Article:** Clinical interpretation of bilirubin levels: when and how to measure fractions (2020)
**Journal:** American Family Physician
**Section:** abstract | **Similarity:** 0.626

Total bilirubin measurement is a routine component of liver function testing. However,
fractionation into direct (conjugated) and indirect (unconjugated) bilirubin provides critical diagnostic
information. Total bilirubin levels above 2.5 mg/dL typically warrant fractionation. Indirect hyperbilirubinemia
suggests hemolysis, ineffective erythropoiesis, or inherited disorders like Gilbert syndrome. Direct hyperbilirubinemia
indicates hepatocellular dysfunction or biliary obstruction. This article provides a practical algorithmic approach
to hyperbilirubinemia evaluation, emphasizing cost-effective testing strategies and appropriate specialist referral.

---

### Chunk 17/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.626

swillshowelevatedCBand/orUCBconcentrations.Thesediseasesareassociatedwithconcomitantliverlesionsofdifferentseveritythatmaycompromiseliverfunctionandmightfollowanacuteorchroniccourse.Espe-ciallyinthecaseofacutehepatocellulardamage,hepato-cellularnecrosisinducesanincreaseintransaminases.Thehepatocellulardiseasesthatmaycausehyperbilirubinemiaare:viralhepatitis,alcoholichepatitis,metabolicsteatohe-patitis,toxichepatitis,Wilsondisease,hemochromatosis,autoimmunehepatitis,α1-antitrypsindeciency,ischemichepatitis,andBudd–Chiarisyndrome.WithconcurrentelevationofunconjugatedbilirubinInpatientswithalterationsinliveruptakeand/orconju-gation,UCBaccumulates,anditsconcentrationsincreaseinblood,whereasCBdecreases.Thisoriginatesadecreaseinurobilinogenconcentrations,whichcanbeobservedin
urineandfeces(acholia).Bilirubindoesnotincreaseinurine(nocholuria),sinceUCBisnotwater-solubleandisnotfilteredbythekidneys.Medicationssuchasrifampicin,chloramphenicol,andprobenecidmayinduceunconjugatedhyperbilirubinem

---

### Chunk 18/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.623

n, is positively associated with insulin resistance. 
Antioxidants 12, 170 (2023).11. Vítek, L., Zelenka, J., Zadinová, M. & Malina, J. The impact of 
intestinal microlora on serum bilirubin levels. J. Hepatol. 42, 238243 (2005).12. Vítek, L. et al. Intestinal colonization leading to fecal  urobilinoid excretion may play a role in the pathogenesis of 
neonatal jaundice. J. Pediatr. Gastroenterol. Nutr. 30, 294298 (2000).13. Poland, R. L. & Odell, G. B. Physiologic jaundice: the 
enterohepatic circulation of bilirubin. N. Engl. J. Med. 284, 16 (1971).14. Brodersen, R. & Hermann, L. S. Intestinal reabsorption of 
unconjugated bilirubin. A possible contributing factor in neonatal 
jaundice. Lancet 1, 1242 (1963).15. Gustafsson, B. E. & Lanke, L. S. Bilirubin and urobilins in germfree, 
ex-germfree, and conventional rats. J. Exp. Med. 112, 975981 (1960).16. Midtvedt, T. & Gustafsson, B. E. Microbial conversion of bilirubin 
to urobilins in vitro and in vivo. Acta Pathol.

---

### Chunk 19/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** results | **Similarity:** 0.623

is indicated by a shaded blue area on the plot. b, Comparison of bilR absence in samples from healthy adults and infants in their first month of life. c, Comparison of the percentage of samples with no bilR detected from healthy adults and adults with IBD (Crohns disease 
(CD) or ulcerative colitis (UC)). The number of metagenomic samples included in 
each dataset is indicated above each bar. The P values for each comparison show the results of a test of equal proportions to determine whether the fraction of 
samples with no bilR detected was different between groups, without adjusting for multiple testing.

Nature Microbioogy | Voume 9 | January 2024 | 173184180
foundational knowledge that will serve as the basis of future investi-gations of the importance of bilirubin metabolism in human health.MethodsCulture methodsAnaerobic bacteria. Bacterial strains were obtained from the NIH Biodefense and Emerging Infections Research Resources Repository (BEI).

---

### Chunk 20/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.619

thantherateofbili-rubinproduction[39].However,hyperbilirubinemiaisalong-establishedmarkerofliverandbilealterations,andhasprognosticvalueincertainliverdiseases[3,40].Inthehyperacutestageofacuteliverfailure,bilirubinconcentrationisrelativelylowascomparedtothesub-stantialelevationofplasmaaminotransferaseconcentra-tionsinplasma.However,inthesubacutestage,the358
GuerraRuizetal.:Bilirubin:measurementandclinicalusefulness

situationreverses[41].Inthiscase,elevatedlevelsofbili-rubininplasmaareanindicatorofpoorprognosisandmortality[42].Hyperbilirubinemiadoesnothaveaprognosticvalueinpatientswithacutehepatitisinducedbyparacetamol,butitdoesinacuteandsubacutehepatitisinducedbyothercauses[43].Bilirubinconcentrations>17.6mg/dLisanindicationforhospitalizationinpatientswithacute
hepatitisunrelatedtotheintakeofparacetamol[44].Hepaticcirrhosiscanbeaccompaniedbyprogressivebilirubinelevations.Increasedbilirubinconcentrationsarearelativelylateeventinchronicliverdiseaseandindicatesevereliverdysfunction[4].In

---

### Chunk 21/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.619

of gut microbial bilirubin reduction affects serum bilirubin levels, which can have substantial health implications.  In moderate concentrations, bilirubin serves as an important anti-oxidant with potential health benefits6,7. However, elevated serum bilirubin concentrations can become toxic, leading to jaundice and, in extreme cases, kernicterus, a type of bilirubin-induced neurologi-cal damage8. Similarly, urobilinogen can be reabsorbed and has been associated with multiple diseases, highlighting the key role of bilirubin reduction in the homeostasis of multiple metabolites35,9,10.

---

### Chunk 22/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** methods | **Similarity:** 0.614

ycausereduceshepatocytecellnumberandmayimpairtheuptakeofindirectbilirubinfromplasmaanddiminishdirectbilirubintransportandclearance
throughthebileducts.Variousanalyticalmethodsare
currentlyavailableformeasuringbilirubinanditsmetabo-
litesinserum,urineandfeces.Serumbilirubinisdeter-
minedby(1)diazotransferreaction,currently,thegold-
standard;(2)high-performanceliquidchromatography
(HPLC);(3)oxidative,enzymatic,andchemicalmethods;(4)
directspectrophotometry;and(5)transcutaneousmethods.

---

### Chunk 23/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** results | **Similarity:** 0.614

art failure9,10. This further highlights the complexity and importance of the haem degra-dation pathway, confirming the key role that bilirubin reductase plays in determining the balance of multiple health-relevant metabolites.The differences observed between the metagenomes of healthy individuals and those of patients with IBD highlight the potential dis-ruption of bilirubin metabolism in IBD. The lowered prevalence of bilirubin-reducing bacteria in patients with IBD leads us to hypoth-esize that the disruption of bilirubin metabolism combined with the previously established increase in unconjugated primary bile acids in patients with IBD could contribute to the increased incidence of calcium bilirubinate gallstones that has been observed in these patients25,35. While these results suggest a role for bilirubin-metabolizing microor-ganisms in these diseases, more work is needed before any conclusions can be made.

---

### Chunk 24/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.613

trifugation at 3,260 × g for 6min. The supernatant was filtered through a non-sterile 0.22µm filter. Chloro-form (5ml; Sigma-Aldrich) was added to the filtered supernatant and 
separated via organic extraction in a separatory funnel. The resultant chloroformurobilinogen solution was air-dried until the chloroform was completely evaporated, producing the extract used in the subse-
quent fluorescence assays and LCMS/MS.Because the urobilinogen product of bilirubin reduction is unsta-ble in oxygen, measuring urobilinogen itself was infeasible. Therefore, to measure bilirubin reduction, urobilinogen was oxidized to urobilin via the addition of iodine. The urobilin was quantified by adding zinc acetate solution to form a fluorescent zincurobilin complex3638. However, this assay also detects stercobilin, which fluoresces at the same wavelength as urobilin39,40.

---

### Chunk 25/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** results | **Similarity:** 0.611

noglucuronide,andbilirubindiglucuronide(indirect-reactionfractions)[18].Afourthfractionresultsfromcovalentbindingofbilirubintoprotein(δ-bilirubin),whichisdifferentfromthebilirubin–albumincomplexinserum[1].DiazomethodThereactionofbilirubinwiththediazoreagentrenderstwocolorazodipyrroles(azopigments)(Figure1(D))thatcanbemeasuredbyspectrophotometry,at530nmtoneutraloracidpH,andat598nmtoalkalinepH(i.e.,bytheadditionofalkalinetartrate).Thisreactionisacceleratedbyalcoholand
avarietyofothercomponents(i.e.,sodiumbenzoate)causingUCBtodissociatefromalbumin[19].Inthepresenceofan‘accelerator’,conjugatedandunconjugatedbilirubinarejointlymeasured(totalbilirubin),whereasintheabsenceofanaccelerator,onlyCBreacts(‘directbilirubin’).ThedifferencebetweenTotalandCByieldsUCBcon-centration(‘indirectbilirubin’).Forthemethodtobeaccurate,itiscrucialthatminimumamountsofUCBreactinthedirectprocedure.ThediazomethoddescribedbyJendrassik&Grofin1938[20]andlatermodiedbyDoumasetal.[21]yieldstotalserumbilir

---

### Chunk 26/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.611

holia).Bilirubindoesnotincreaseinurine(nocholuria),sinceUCBisnotwater-solubleandisnotfilteredbythekidneys.Medicationssuchasrifampicin,chloramphenicol,andprobenecidmayinduceunconjugatedhyperbilirubinemia,sinceitcompeteswiththetransporterthatcarriesbilirubinintothehepatocyte.TheelevationofUCBisalsoassociatedwithinheriteddisordersaffectingconjugation,ofwhichGilbertsyndromeisthemostcommoninadults,affecting3–10%ofthepopulation.UDPGTactivityislow.Thissyndromedoesnot
requirefollow-uportreatment,sinceitisabenigndisorder.However,itmaybeaconfoundingfactorwhenscreeningforliverdiseaseandisfrequentlymisdiagnosedaschronichepatitis[3].Whenthegeneticdefectdirectlyaffectsenzymepro-duction,itcausesCrigler–Najjarsyndrome(SCN).SCNtype1ischaracterizedbyatotalenzymedeficiencythatdoesnotimprovewithinductiontherapywithpheno-barbital.Thissubtypemaybelife-threateningduetothe
neurologicaltoxicitysecondarytothedepositionofbili-rubininthebasalgangliaandnucleiofthebrainstem(neonatalkernicterus)[36].InSCNtype2,e

---

### Chunk 27/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.611

d Data Fig. 1), and measured via fluorescence, while non-protein-bound bilirubin is not fluorescent18. As a positive control, we showed that the known bilirubin reducer, Clostridioides difficile CD3, returned a positive result in the fluorescence assay and that no fluorescence was produced when no bilirubin was added to the culture (Fig. 1c and Extended Data Fig. 2)19.of gut microorganisms in bilirubin reduction, the gut microbial enzyme that reduces bilirubin to urobilinogen, hereafter called bilirubin reduc-tase, has remained undiscovered15. Multiple bilirubin-reducing bacte-ria have been identified, including strains of Clostridioides difficile12, Clostridium ramosum16, Clostridium perfringens12 and Bacteroides  fragilis17, but much of this work was performed before genome sequenc-ing was widely available, making it difficult to know which strains were studied.

---

### Chunk 28/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.609

of breast cancer in a case control study. J. Nutr. 132, 303306 (2002).7. Osiak, W., Wątroba, S., Kapka-Skrzypczak, L. & Kurzepa, J. Two 
faces of heme catabolic pathway in newborns: a potential role 
of bilirubin and carbon monoxide in neonatal inlammatory 
diseases. Oxid. Med. Cell. Longev. 2020, 7140496 (2020).8. Kapitulnik, J. Bilirubin: an endogenous product of heme 
degradation with both cytotoxic and cytoprotective properties. 
Mol. Pharmacol. 66, 773779 (2004).9. Stenemo, M. et al. The metabolites urobilin and sphingomyelin 
(30:1) are associated with incident heart failure in the general 
population. ESC Heart Fail. 6, 764773 (2019).10. Kipp, Z. A. et al. Bilirubin levels are negatively correlated 
with adiposity in obese men and women, and its catabolized 
product, urobilin, is positively associated with insulin resistance. 
Antioxidants 12, 170 (2023).11. Vítek, L., Zelenka, J., Zadinová, M. & Malina, J.

---

### Chunk 29/30
**Article:** BilR is a gut microbial enzyme that reduces bilirubin to urobilinogen (2024)
**Journal:** Nature Microbiology
**Section:** other | **Similarity:** 0.609

t of microbial bilirubin metabolism on serum bilirubin levels in rats1114.Gut microorganisms are solely responsible for the reduction of bilirubin to urobilinogen, potentially using the molecule as a terminal electron acceptor in anaerobic respiration. Despite the recognized role 
Received: 15 March 2023Accepted: 7 November 2023Published online: 3 January 2024
 Check for updates
1Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, College Park, MD, USA. 2Center for Bioinformatics and Computational Biology, University of Maryland, College Park, College Park, MD, USA. 3National Library of Medicine, National Institutes of Health, Bethesda, MD, USA. 4Division of Molecular and Cellular Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA. 5Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, USA.

---

### Chunk 30/30
**Article:** Measurement and clinical usefulness of bilirubin in liver disease (2021)
**Journal:** Advances in Laboratory Medicine
**Section:** other | **Similarity:** 0.609

tedresponsibilityfortheentirecontentofthismanuscriptandapproveditssubmission.Competinginterests:Authorsstatenoconictofinterest.References1.CappelliniMD,LoSF,SwinkelsDW.38–Hemoglobin,iron,bilirubin.In:Tietztextbookofclinicalchemistryandmoleculardiagnostics,6thed.St.Louis,MO,USA:ElsevierInc.;2017.https://doi.org/10.1016/B978-0-323-35921-4.00038-7.2.Méndez-SánchezN,QiX,VitekL,ArreseM.Evaluatinganoutpatientwithanelevatedbilirubin.AmJGastroenterol2019;114:1185–8.3.DufourDR,LottJA,NolteFS,GretchDR,KoffRS,SeeffLB.Diagnosisandmonitoringofhepaticinjury.II.Recommendationsforuseoflaboratorytestsinscreening,diagnosis,andmonitoring.Clin
Chem2000;46:2050–68.4.FeveryJ.Bilirubininclinicalpractice:areview.LiverInt2008;28:592–605.5.VítekL.Bilirubinasapredictorofdiseasesofcivilization.Isittimetoestablishdecisionlimitsforserumbilirubinconcentrations?ArchBiochemBiophys2019;672:108062.

---

